Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
Br J Cancer
; 127(5): 916-926, 2022 09.
Article
in En
| MEDLINE
| ID: mdl-35618786
Full text:
1
Collection:
01-internacional
Health context:
6_ODS3_enfermedades_notrasmisibles
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Chemokine CXCL1
/
Signaling Lymphocytic Activation Molecule Family
Type of study:
Qualitative_research
Limits:
Female
/
Humans
Language:
En
Journal:
Br J Cancer
Year:
2022
Document type:
Article